Mr. Jim Breslin:

On the two-stage process, PwC says it is used and it has benefits but the issue in this - I am summarising the PwC findings - is in its execution. Before I would go near two stage again, I would want to absolutely scrutinise and have a full range of expertise look at the maturity of the design that we would go to the market with and the controls that would be implemented to get to the GMP so that we would not end up with a delayed GMP, and one with an escalating price, as took place in this case.

Two stage is an unusual approach. For most of the healthcare facilities we use, we will not use two stage. If there was a particular circumstance where there were a lot of arguments for two stage, based on this experience, I would want it to be absolutely invigilated that it was going to be a two stage that would execute well.